AZ-D516NC00001-TROPION-LUNG14
Phase III
OPEN TO ACCRUAL *
A Phase III, Open-Label, Randomised Study of Osimertinib with or without Datopotamab Deruxtecan (Dato-DXd), as First-Line Treatment in Participants with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NEOGENE-NT-112-301
Phase I
OPEN TO ACCRUAL
An Open-Label, Phase 1, Multi-Center Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation
NEOGENE-NT-175-201
Phase I
OPEN TO ACCRUAL
An Open-Label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation